Livzon Pharmaceutical Group Inc., founded in January 1985 with a registered capital of 953 million yuan, is a comprehensive Pharmaceutical Group company integrating Pharmaceutical research and development, production and sales with more than 8,000 employees. In 1993, Lizon's A and B shares were listed successively. In 2014, the company completed the transfer of B shares to H shares, and is one of the few A+H shares listed pharmaceutical companies in the capital market.

In 2019, the total assets of the company are 17.976 billion yuan, the annual operating income is 9.385 billion yuan, the net profit is 1.462 billion yuan, and the R&D investment is 827 million yuan.

Rezon is committed to ensuring that its products are effective, safe and stable. Group pharmaceutical enterprises have established a sound quality management system. Up to 2019:31 production lines of 4 pharmaceutical enterprises have passed GMP certification; 28 varieties of 4 API enterprises have passed GMP certification, and 11 varieties have passed veterinary GMP certification; API has passed the international certification field inspection of 15 varieties, 20 international certification certificates.